Klein Kerstin, Gay Steffen
Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.
Curr Opin Rheumatol. 2015 Jan;27(1):76-82. doi: 10.1097/BOR.0000000000000128.
To give an overview of recently published articles addressing the role of epigenetic modifications in rheumatoid arthritis (RA). Here we focused on DNA methylation and posttranslational histone modifications.
Recent studies attempted to link epigenetic modifications with genetic or environmental risk factors for RA. There is evidence that histone deacetylases confer effects of environmental triggers such as smoking, diet or therapy on expression levels of target genes. Additionally, disturbed methylation patterns and cell-type specific histone methylation marks were identified as potential mediators of genetic risk in RA. Altered methylome signatures were found in several cell types in RA, first of all RA synovial fibroblasts, and contribute to the intrinsic fibroblast activation. The reversal of DNA hypomethylation by inhibiting the polyamine recycling pathway was suggested as new epigenetic therapy in RA. Moreover, targeting epigenetic reader proteins, such as bromodomain proteins, emerged as a new field in drug development and the first studies underscored the potential of these drugs not only in malignant and inflammatory conditions but also in autoimmune diseases.
Epigenetic factors represent a promising area to link genetics, regulation of gene expression and environmental risk factors.
概述近期发表的关于表观遗传修饰在类风湿关节炎(RA)中作用的文章。在此,我们重点关注DNA甲基化和组蛋白翻译后修饰。
近期研究试图将表观遗传修饰与RA的遗传或环境风险因素联系起来。有证据表明,组蛋白脱乙酰酶介导吸烟、饮食或治疗等环境触发因素对靶基因表达水平的影响。此外,甲基化模式紊乱和细胞类型特异性组蛋白甲基化标记被确定为RA遗传风险的潜在介导因素。在RA的几种细胞类型中发现了甲基化组特征改变,首先是RA滑膜成纤维细胞,这有助于成纤维细胞的内在激活。通过抑制多胺循环途径逆转DNA低甲基化被认为是RA新的表观遗传治疗方法。此外,靶向表观遗传阅读蛋白,如溴结构域蛋白,已成为药物开发的一个新领域,首批研究强调了这些药物不仅在恶性和炎症性疾病中,而且在自身免疫性疾病中的潜力。
表观遗传因素是连接遗传学、基因表达调控和环境风险因素的一个有前景的领域。